NCT01063088已完成3 期
An Open Label, Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 211
- 试验地点
- 4
- 主要终点
- To assess the safety of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season in an adult population through the first seven post vaccination days
研究概览
简要总结
The purpose of the study is to verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to World Health Organization (WHO)/European Union (EU) recommendation for the 2009/2010 season.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 59 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is 18 to 59 years of age, inclusive, at the time of screening
- •Subject has given written informed consent prior to study entry
- •Subject is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination, such that the investigator would not hesitate to provide routine influenza immunization to the subject in the course of routine medical practice
- •Subject agrees to keep a daily record of symptoms for the duration of the study
- •If female of childbearing potential, subject presents with a negative urine pregnancy test immediately prior to vaccination on Study Day 1 and agrees to employ adequate birth control measures for the duration of the study
- •Subject is willing and able to comply with the requirements of the protocol
排除标准
- •Subject has a history of severe allergic reaction or anaphylaxis
- •Subject has an oral temperature of >= 37.5°C on the day of vaccination in this study Subject has a dermatologic condition or tattoos, which may interfere with injection site reaction rating
- •Subject has received a live vaccine within 4 weeks or an inactivated or subunit vaccine within 2 weeks of study entry
- •Subject has been vaccinated with seasonal influenza vaccine for the 2009/2010 season
- •Subject currently has or had a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
- •Subject has any inherited or acquired immunodeficiency
- •Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (> 800 μg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs.
- •Subject has a functional or surgical asplenia
- •Subject has a known or suspected problem with alcohol or drug abuse
- •Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie., children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study.
- •If female, subject is pregnant or lactating at the time of study enrollment
- •Subject has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
研究组 & 干预措施
Vaccination
Experimental
Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
干预措施: Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures) (Biological)
结局指标
主要结局
To assess the safety of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season in an adult population through the first seven post vaccination days
时间窗: 7 days
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Yearly Strain Variation Study, 2010/2011Seasonal InfluenzaInfluenzaNCT01157702Resilience Government Services, Inc.110
已完成
3 期
Yearly Strain Variation Study, 2009/2010Seasonal InfluenzaInfluenzaNCT00943657Alachua Government Services, Inc.110
已完成
3 期
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk GroupsInfluenzaNCT00711295Resilience Government Services, Inc.3,583
已完成
3 期
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 YearsHealthy SubjectsNCT00761631Pfizer1,200
已完成
3 期
rVWF IN PROPHYLAXISVon Willebrand DiseaseNCT02973087Takeda29